Open an account

Spyre Therapeutics

SYRE · NASDAQ

$91.40+$6.68 (+7.88%)TodayMarket closed ·
Prev close $84.72

About SYRE

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. The company is headquartered in Waltham, Massachusetts and currently employs 102 full-time employees. The company went IPO on 2016-04-07. Its pipeline includes investigational extended half-life antibodies targeting a4b7, TL1A, and IL-23. Its pipeline programs include SPY003, SPY004, SPY130, SPY230, SPY002, SPY001, and SPY120. Its advanced product candidate, SPY001, is a fully human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4b7 integrin being developed for the treatment of IBD. Its co-lead program, SPY002, has nominated two fully human mAb candidates designed to bind to tumor necrosis factor-like ligand 1A (TL1A), both of which are in preclinical development for the treatment of IBD. SPY003 is a preclinical-stage program designed to bind to Interleukin 23 (IL-23) and incorporates half-life extending modifications.

Employees
102
Headquarters
Waltham, Massachusetts
Listed
Apr 7, 2016
Sector
Health Care
Industry
Biotechnology
Website
spyre.com

SYRE key statistics

Market cap
8.44B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.53M
Volume
1.71M
Open price
$85.12
High today
$93.22
Low today
$85.08
52 Week high
$110.18
52 Week low
$21.15

Spyre Therapeutics (SYRE) at a glance

Spyre Therapeutics (SYRE) last traded at $91.40, with a market cap of 8.44B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $85.08 and $93.22. The current price is 7.4% above the day's low and 2.0% below its high.

Volume so far is 1.71M shares, in line with the average of 1.53M shares a day.

Over the past year Spyre Therapeutics has ranged from $21.15 to $110.18, and now sits 79% of the way up that range.

Spyre Therapeutics met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.36 per share against an estimate of -$0.7738.

The average analyst price target is $123.11, 34.7% above the current price, from 16 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

94%of 16 analyst ratings say Buy
  • Buy93.8%
  • Hold6.3%
  • Sell0.0%
Price target · 15 analystsAvg $123.11
Low
$97.97
Now
$91.40
High
$136.50

SYRE earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 39.1% on average.

  1. Q3 FY24: reported -$1.36 per share against an estimate of -$0.8409
  2. Q4 FY24: reported -$0.81 per share against an estimate of -$1.01
  3. Q1 FY25: reported -$0.60 per share against an estimate of -$0.8578
  4. Q2 FY25: reported -$0.77 per share against an estimate of -$0.7687
  5. Q3 FY25: reported -$0.15 per share against an estimate of -$0.7613
  6. Q4 FY25: reported -$0.70 per share against an estimate of -$0.7903
  7. Q1 FY26: reported -$0.74 per share against an estimate of -$0.6794
  8. Q2 FY26: reported -$0.36 per share against an estimate of -$0.7738

SYRE news

  • Avi Kapoor

    Crude Oil Edges Lower; Lamb Weston Shares Surge Following Upbeat Q1 Earnings

  • Avi Kapoor

    Hewlett Packard Enterprise, Capital Bancorp, FormFactor And Other Big Stocks Moving Higher On Wednesday

  • Vandana Singh

    Spyre Therapeutics Says Rheumatoid Arthritis Program Misses Internal Benchmark, Stock Tumbles

  • Vandana Singh

    What's Going On With Spyre Therapeutics Stock On Wednesday?

  • Press releaseGlobe Newswire

    Phase 2 Data could Transform these Biotechs from Clinical Promise to Market Validation

  • Press releaseGlobe Newswire

    Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients

  • Press releaseGlobe Newswire

    Spyre Therapeutics to Participate in Stifel 2025 Virtual Immunology and Inflammation Forum

  • Press releasePRNewswire

    Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts

Similar companies

Companies in the same industry as Spyre Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.